The application of PARP inhibitors in the treatment of prostate cancer was initiated in 2015 following the finding that 19.6% of prostate cancers had BRCA1, BRCA2 or ATM mutations (Mandelker et al., 2017). This evidence concerns the gene PARP1 and prostate cancer.